Nasus Pharma Ltd

Nasus Pharma has a market capitalization of $34.78 million, with a current market price of $2.97 per share. The company has 11.71 million shares outstanding, with no dilution from potential share issuance, as the diluted and basic shares are equal. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available for Nasus Pharma, as the valuation snapshot does not include return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry peers or the cohort median for the Pharmaceuticals industry. The company's revenue concentration and geographic exposure are not disclosed in the available data. As a result, it is unclear whether Nasus Pharma has a diversified revenue base or is heavily reliant on a specific geographic region or product line. Growth trajectory is difficult to assess due to the absence of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of $20.00, with a median of $20.00, indicating a potential upside of 579% from the current market price. However, the lack of strong-buy recommendations and the absence of a hold rating suggest a cautious outlook from the analyst community. The company's risk profile is marked by low dilution risk and an inability to assess liquidity risk. No significant risk factors are disclosed in the available documents, and there is no indication of near-term dilution pressure from recent issuance or shelf registration. Recent events and filings are not disclosed in the available data, making it difficult to assess any material developments that may have impacted the company's operations or financial position in the near term.